Clinical trial
TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
NCT00140309 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00140309 |
|---|---|
| Title | TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment |
| Official title | TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tuberculosis, Pulmonary |
| Intervention type | Drug |
| Interventions | moxifloxacin (with isoniazid, rifampin, pyrazinamide) |
| Enrollment | 350 |
| Start date | Jul 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Sep 1, 2005 |
| Last update posted | Mar 19, 2007 |
| Countries | Canada, South Africa, Uganda, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: